Close
The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Professor Stephen Neidle’s ‘G-Quadruplex’ Targeting project, which has the potential to treat pancreatic and other cancers.
Pancreatic cancer is devastating and almost always refractory to treatment, resulting in rapid and near-invariably fatal disease progression, usually within a few months of diagnosis. This outlook has not changed in over 40 years despite significant advances in the understanding of disease mechanisms, and the availability of many new cancer therapies. It represents one of the most significant unmet needs in oncology, and indeed in medicine in general.
